<DOC>
	<DOCNO>NCT02993237</DOCNO>
	<brief_summary>The primary purpose study assess acceptability swallow darunavir/cobicistat ( DRV/COBI ) darunavir/cobicistat/emtricitabine/tenofovir alafenamide ( D/C/F/TAF ) fixed-dose combination ( FDC ) tablet , use match placebo tablet , human immunodeficiency virus ( HIV ) -1 infected adolescent patient .</brief_summary>
	<brief_title>Study Assess Acceptability/Swallowability DRV-Containing FDC Tablets HIV-1 Infected Adolescents , Using Matching Placebo Tablets</brief_title>
	<detailed_description />
	<criteria>Participant must male female 12 17 year age , inclusive Participant must body weight least 40 kilogram ( kg ) Informed consent must obtain ( participant and/or his/her parent ( ) /legal guardian , applicable ) ageappropriate Assent Form , applicable , indicate purpose , procedure require , study understood participant willing participate study Participant must able comply protocol requirement , adhere prohibition restriction specify protocol Participant document chronic human immunodeficiency virus ( HIV ) 1 infection , aware his/her HIV1 diagnosis Participant must stable antiretroviral ( ARV ) regimen least 3 month document plasma HIV1 ribonucleic acid ( RNA ) less ( &lt; ) 50 copies/ milliLitre ( mL ) within 3 month prior screen Participant must willing ass swallowability placebo tablet able ( demonstrated intake reference placebo tablet ) Participant condition , opinion Investigator , would compromise study wellbeing participant , prevent participant meeting perform study requirement Participant condition , opinion Investigator , could prevent , limit , confound protocolspecified assessment Participant active clinically significant physical psychological disease finding screen , Investigator 's opinion , would compromise participant 's safety , ability swallow ( eg , candidiasis ) , outcome study Participant history difficulty oral intake ARV therapy medication Participant take disallow concomitant medication overthecounter product Participant family member employee Investigator study site Participant family member employee Johnson &amp; Johnson</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>